The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...
More than half of all American adults, almost 137 million people, could be candidates for the blockbuster GLP-1 drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback